PaulDMillerMD

Distinguished Clinical Professor of Medicine, University of Colorado Health Sciences Center

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
6655 West Jewell Avenue
Suite 2
Lakewood, CO 80232
Phone+1 303-284-2352

Fax+1 303-284-2384

University of ColoradoFellowship, Nephrology, 1974 - 1976
University of RochesterChief Residency, Internal Medicine, 1973 - 1974
University of RochesterResidency, Internal Medicine, 1970 - 1973
George Washington University School of Medicine and Health SciencesClass of 1970

PubMed

23 citations
Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
Ruban Dhaliwal, Didier Hans, Gary Hattersley, Bruce Mitlak, Lorraine A Fitzpatrick
JBMR Plus. 2020-04-01
3 citations
Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM an...
Ethel S. Siris, Michele McDermott, Nicola Pannacciulli, Paul D. Miller, E. Michael Lewiecki
JBMR Plus. 2020-02-24
25 citations
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
John P. Bilezikian, Gary Hattersley, Bruce H. Mitlak, Ming-yi Hu, Lorraine A. Fitzpatrick
Current Medical Research and Opinion. 2019-09-11

Romosozumab Safe in Osteoporosis with Mild-Moderate Renal DiseaseOctober 19th, 2019
Romosozumab Benefits Osteoporosis Patients Regardless of Renal InsufficiencyOctober 7th, 2019